Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

“…Rituximab treatment has also demonstrated to be effective in seronegative AIDs, as for example cutaneous vasculitis and ANCA-negative vasculitis. 60,61,62 Autoimmune encephalitis is a rare but dreadful irAE that is often associated with double checkpoint blockade, as reported in different tumor types. Cases have been reported in which anti-neural autoantibodies were detected, such as anti-NMDAR 63 or anti-Hu 64 ; in other cases, such antibodies were undetectable.…”

Immunotherapy in Eosinophilic Granulomatosis with Polyangiitis: A New Step Forward?

“…Patients with positive ANCA testing were significantly more likely to achieve remission at 12 months: 80% (12/15) who were ANCA-positive versus 36% (8/21) who were ANCA-negative. In contrast, Thiel et al have reported in 9 patients, that rituximab appeared to be an efficient and safe treatment for both ANCA-positive and ANCA-negative patients [23], as also mentioned by Novikov et al [25]. Largest prospective studies will have to clarify this issue.…”

“…It has also been shown that rituximab mediates its beneficial actions in EGPA, at least in part, through the inhibition of T-cell IL-5 production [19]. It is interesting to note that Novikov et al reported that all patients had improvement of their asthmatic symptoms [25].…”

“…Furthermore, recent case reports and small retrospective series [18][19][20][21][22][23][24][25] have indicated that rituximab may also be an effective remission induction agent in refractory or relapsing EGPA. A review of published series of rituximab for EGPA patients is shown in Table 1.…”

Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis

“…The majority of patients with EGPA respond to glucocorticoids ± immunosuppressive agents 3 , though a significant proportion of them develop relapses and may require biologic treatment 4 . Novel biomarkers of disease activity for EGPA are needed because the clinical value of eosinophil count, serum IgE, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in treated patients is low 5 .…”